Ramucirumab is approved by the FDA in combination with docetaxel in patients with progression after platinum-based chemotherapy in NSCLC. Which of the following is not true regarding ramucirumab in NSCLC

Q. Ramucirumab is approved by the FDA in combination with docetaxel in patients with progression after platinum-based chemotherapy in NSCLC. Which of the following is not true regarding ramucirumab in NSCLC :

A.            Its a murine IgG1 monoclonal antibody, specific to the VEGFR2

B.            In the trial leading to its approval, ramucirumab in combination with docetaxel demonstrated superior ORR, PFS, and OS versus docetaxel monotherapy

C.            Both of the above

Answer: Its a murine IgG1 monoclonal antibody, specific to the VEGFR2